Edition:
United States

Boston Scientific Corp (BSX)

BSX on New York Consolidated

41.66USD
19 Jun 2019
Change (% chg)

$0.72 (+1.76%)
Prev Close
$40.94
Open
$40.80
Day's High
$41.77
Day's Low
$40.58
Volume
6,328,720
Avg. Vol
7,834,469
52-wk High
$41.99
52-wk Low
$31.56

Latest Key Developments (Source: Significant Developments)

H.I.G. Biohealth Partners Completes Sale Of Vertiflex To Boston Scientific
Tuesday, 18 Jun 2019 06:00am EDT 

June 18 (Reuters) - Boston Scientific Corp ::H.I.G. BIOHEALTH PARTNERS COMPLETES SALE OF VERTIFLEX TO BOSTON SCIENTIFIC.H.I.G. BIOHEALTH PARTNERS SAYS DEAL FOR A TOTAL EQUITY VALUE OF APPROXIMATELY $465 MILLION IN CASH.H.I.G. BIOHEALTH PARTNERS SAYS DEAL INCLUDES ADDITIONAL PAYMENTS CONTINGENT ON COMPANY ATTAINING CERTAIN COMMERCIAL GOALS.  Full Article

Third Point Takes Share Stake In Boston Scientific, United Technologies
Wednesday, 15 May 2019 04:01pm EDT 

May 15 (Reuters) - Third Point LLC::THIRD POINT LLC TAKES SHARE STAKE OF 5 MILLION SHARES IN BOSTON SCIENTIFIC.THIRD POINT LLC TAKES SHARE STAKE OF 6.5 MILLION SHARES IN UNITED TECHNOLOGIES CORP.THIRD POINT LLC CUTS SHARE STAKE IN AMERICAN EXPRESS TO 1.5 MILLION SHARES FROM 2.9 MILLION SHARES.THIRD POINT LLC TAKES SHARE STAKE IN COLFAX CORP OF 2 MILLION SHARES - SEC FILING.THIRD POINT LLC: CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DECEMBER 31, 2018.  Full Article

Jana Partners LLC Dissolves Stake In Anthem, Autodesk
Wednesday, 15 May 2019 08:05am EDT 

May 15 (Reuters) - Jana Partners LLC::JANA PARTNERS LLC DISSOLVES SOLE SHARE STAKE IN ANTHEM INC - SEC FILING.JANA PARTNERS LLC DISSOLVES SOLE SHARE STAKE IN BOSTON SCIENTIFIC CORP.JANA PARTNERS LLC DISSOLVES SOLE SHARE STAKE IN AUTODESK INC.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN HD SUPPLY HOLDINGS INC BY 49.3 PERCENT TO 2.7 MILLION SHARES.JANA PARTNERS - CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DECEMBER 31, 2018.  Full Article

Boston Scientific Announces Agreement To Buy Vertiflex Inc
Thursday, 9 May 2019 06:45am EDT 

May 9 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE VERTIFLEX, INC..BOSTON SCIENTIFIC CORP - TRANSACTION CONSISTS OF $465 MILLION IN UPFRONT CASH.BOSTON SCIENTIFIC - TRANSACTION CONSISTS OF $465 MILLION IN UPFRONT CASH AND ADDITIONAL PAYMENTS CONTINGENT ON COMMERCIAL MILESTONES FOR NEXT THREE YEARS.BOSTON SCIENTIFIC CORP - TRANSACTION IS EXPECTED TO BE IMMATERIAL TO ADJUSTED EARNINGS PER SHARE IN 2019 AND 2020.BOSTON SCIENTIFIC CORP - TRANSACTION IS EXPECTED TO BE ACCRETIVE AFTER 2019 AND 2020.BOSTON SCIENTIFIC- ON A GAAP BASIS, DEAL EXPECTED TO BE LESS ACCRETIVE, OR MORE DILUTIVE DUE TO AMORTIZATION EXPENSE, ACQUISITION-RELATED NET CHARGES..  Full Article

Boston Scientific Receives U.S. FDA Approval For The Vici Venous Stent System
Monday, 6 May 2019 06:45am EDT 

May 6 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR THE VICI VENOUS STENT SYSTEM.BOSTON SCIENTIFIC CORP - U.S FOOD AND DRUG ADMINISTRATION APPROVED VICI VENOUS STENT SYSTEM FOR TREATMENT OF ILIOFEMORAL VENOUS OBSTRUCTIVE DISEASE.  Full Article

Boston Scientific Q1 Adjusted Earnings Per Share $0.35
Wednesday, 24 Apr 2019 06:30am EDT 

April 24 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2019.Q1 GAAP EARNINGS PER SHARE $0.30.Q1 SALES $2.493 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.53 BILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.36 -- REFINITIV IBES DATA.SEES Q2 ADJUSTED EARNINGS PER SHARE $0.37 TO $0.39 EXCLUDING ITEMS.Q1 ADJUSTED EARNINGS PER SHARE $0.35.ESTIMATES REVENUE GROWTH FOR FULL YEAR 2019 TO BE IN A RANGE OF APPROXIMATELY 7 TO 8 PERCENT ON A REPORTED BASIS.SEES FY 2019 GAAP EARNINGS PER SHARE $1.09 TO $1.13.QTRLY CARDIOVASCULAR SALES $972 MILLION VERSUS $933 MILLION.ESTIMATES FY19 ADJUSTED EARNINGS, EXCLUDING CERTAIN CHARGES (CREDITS), IN A RANGE OF $1.54 TO $1.58 PER SHARE.COMPANY ESTIMATES Q2 EARNINGS ON A GAAP BASIS IN A RANGE OF $0.23 TO $0.25 PER SHARE.Q2 EARNINGS PER SHARE VIEW $0.39 -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $1.56, REVENUE VIEW $10.68 BILLION -- REFINITIV IBES DATA.BOSTON SCIENTIFIC - ADJUSTED NET INCOME WAS NEGATIVELY IMPACTED BY $11 MILLION IN QUARTER.BOSTON SCIENTIFIC - SEES ABOUT $30 MILLION NEGATIVE IMPACT GLOBALLY TO 2019 REVENUE, INCLUDING AN ABOUT $5 MILLION SALES RETURN RESERVE RECORDED IN Q1.ESTIMATES REVENUE GROWTH FOR Q2 OF 2019 TO BE IN A RANGE OF APPROXIMATELY 5 TO 7 PERCENT ON A REPORTED BASIS.ESTIMATES REVENUE GROWTH FOR Q2 OF 2019 TO BE IN A GROWTH RANGE OF APPROXIMATELY 6 TO 7 PERCENT ON AN ORGANIC BASIS.  Full Article

Boston Scientific Expects About $25 Mln Hit To 2019 Revenue From FDA Decision On Surgical Mesh Products
Wednesday, 17 Apr 2019 06:40am EDT 

April 17 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC CORP - ANTICIPATES AN APPROXIMATE $25 MILLION NEGATIVE IMPACT GLOBALLY TO 2019 FULL YEAR REVENUE FROM FDA DECISION.BOSTON SCIENTIFIC CORP - CONTINUES TO ASSESS ANY POTENTIAL ADDITIONAL IMPACT TO BUSINESS FROM FDA DECISION ON SURGICAL MESH PRODUCTS.  Full Article

Boston Scientific Reports Q4 GAAP Earnings Per Share of $0.27
Wednesday, 6 Feb 2019 06:30am EST 

Feb 6 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2018.Q4 GAAP EARNINGS PER SHARE $0.27.Q4 SALES $2.561 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.56 BILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.37 -- REFINITIV IBES DATA.Q4 ADJUSTED EARNINGS PER SHARE $0.39.ESTIMATES REVENUE GROWTH FOR Q1 OF 2019, VERSUS PRIOR YEAR PERIOD, TO BE IN A RANGE OF APPROXIMATELY 6 TO 7 PERCENT.SEES Q1 EARNINGS ON A GAAP BASIS IN A RANGE OF $0.32 TO $0.33 PER SHARE.SEES Q1 ADJUSTED EARNINGS IN A RANGE OF $0.35 TO $0.36 PER SHARE.BOSTON SCIENTIFIC - ESTIMATES REVENUE GROWTH FOR 2019, VERSUS PRIOR YEAR PERIOD, TO BE IN A RANGE OF APPROXIMATELY 7 TO 9 PERCENT ON A REPORTED BASIS.ESTIMATES REVENUE GROWTH FOR 2019 OF APPROXIMATELY 7 TO 8.5 PERCENT ON AN ORGANIC BASIS.COMPANY ESTIMATES INCOME ON A GAAP BASIS IN A RANGE OF $1.13 TO $1.18 PER SHARE FOR 2019.ESTIMATES ADJUSTED EARNINGS IN A RANGE OF $1.53 TO $1.58 PER SHARE IN 2019.Q1 EARNINGS PER SHARE VIEW $0.37 -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $1.58 -- REFINITIV IBES DATA.  Full Article

Neovasc Announces Dismissal Of Claim Brought By Edwards Lifesciences
Tuesday, 22 Jan 2019 07:30am EST 

Jan 22 (Reuters) - Neovasc Inc ::NEOVASC ANNOUNCES DISMISSAL OF CLAIM BROUGHT BY EDWARDS LIFESCIENCES.  Full Article

Boston Scientific CEO Says Expects To Deliver Double Digit EPS Growth In 2018
Tuesday, 8 Jan 2019 12:12pm EST 

Jan 8 (Reuters) - Boston Scientific Corp ::CEO SAYS EXPECT TO DELIVER DOUBLE DIGIT EPS GROWTH IN 2018 - JP MORGAN CONF.CEO SAYS NO CHANGES TO LAUNCH OF LOTUS SYSTEM; ON TRACK FOR Q1 LAUNCH IN EUROPE AND MID-YEAR IN U.S..CEO SAYS BTG PLC'S <<>> INTERVENTIONAL MEDICINE BUSINESS BRINGS MOST VALUE TO BSX.CEO EXPECTS TAX RATE OF 13 PERCENT AND FOREIGN EXCHANGE IMPACT TO BE NEUTRAL IN 2019 - JP MORGAN CONF.CEO SAYS WILL EXCEED ABOUT $1.1 BILLION IN RESEARCH AND DEVELOPMENT, WITH 30 PERCENT OF SPENDING IN CLINICAL PROJECTS - JP MORGAN CONF.  Full Article

Boston Scientific trims 2019 sales growth forecast on weak first quarter, shares fall

Boston Scientific Corp on Wednesday posted a rare first-quarter profit and revenue miss and lowered the top end of its 2019 sales growth forecast as the medical device maker faces regulatory scrutiny for some of its products.